Wealthfront Advisers LLC Makes New $1.39 Million Investment in Illumina, Inc. $ILMN

Wealthfront Advisers LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, Holdings Channel.com reports. The firm acquired 7,905 shares of the life sciences company’s stock, valued at approximately $1,390,000.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Illumina during the 2nd quarter worth about $3,374,423,000. WCM Investment Management LLC raised its position in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Bank of New York Mellon Corp purchased a new stake in Illumina in the 2nd quarter worth about $293,846,000. Invesco Ltd. lifted its stake in Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,095,958 shares of company stock valued at $401,720,974 over the last quarter. 2.90% of the stock is owned by corporate insiders.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ILMN shares. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Barclays raised their price target on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina has an average rating of “Hold” and an average target price of $188.40.

Illumina Price Performance

Shares of ILMN stock opened at $219.40 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market capitalization of $33.13 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.00 and a beta of 1.45. The company’s 50-day simple moving average is $188.01 and its two-hundred day simple moving average is $152.44. Illumina, Inc. has a one year low of $88.00 and a one year high of $220.43.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the company posted $1.19 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.